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EXTENDING THE BURDEN OF DISEASE PROTOCOL:
DERIVING DISABILITY WEIGHTS FOR RISK FACTOR
DISEASES—THE CASE FOR OSTEOPOROSIS
Janssen M, Birnie E, Bonsel G
Academic Medical Center, Amsterdam, Noord-Holland,The
Netherlands
OBJECTIVES: To compare a newly developed method to derive
disability weights for risk factor diseases, in particular osteo-
porosis, with the standard QALY approach (SQA). A risk factor
disease is an asymptomatic condition with a risk of a sympto-
matic event. SQA estimates burden of risk by multiplying the
probability of an event by the burden of that event, ignoring 
the impact of risk awareness. In osteoporosis, fracture-risk
awareness and associated mortality may affect the burden.
METHODS: Disability weights were derived by a panel of the
general public in The Netherlands (n = 142) as part of a larger
valuation study. All health states were presented to participants
on a standardized, preformatted sheet (‘vignette’) containing
disease speciﬁc information and a generic description (EQ-
6D5L). All vignettes were valued by TTO. Vignettes for 
osteoporosis showed an asymptomatic state with varying 
fracture-risks (1, 2, 5, or 10%), which were valued directly. To
derive osteoporotic weights by SQA osteoporotic fracture
vignettes were included. SQA weights were obtained indirectly;
calculated as hip fracture weight multiplied by fracture risks. 
In total, 14 vignettes were valued, of which three included a 
mortality risk. RESULTS: Taking fracture-risk awareness into
account, mean TTO disability weights for osteoporosis ranged
from 0,035 (1%) to 0,151 (10%). Calculated SQA weights are
0,001 (1%) to 0,011 (10%), a factor 9 to 34 lower. CONCLU-
SIONS: The burden of disease in risk factor diseases (osteo-
porosis) can be quantiﬁed via disability weights using direct
methods. Ignoring fracture-risk awareness and associated mor-
tality leads to gross underestimation of the burden of osteo-
porosis. The inclusion of burden of risk would signiﬁcantly
inﬂuence current QALY/DALY disease rankings and would
accommodate the empirical gap between SQA and the clinical
practice. It would better explain the sizeable resources spent on
risk ‘management’ (e.g. diagnostic tests, disease surveillance) and
prevention in terms of cost per QALY.
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OBJECTIVES: To evaluate persistence of weekly drug treatment
with alendronate and risedronate over 12 months in primary
care patients using the DIN-LINK observational database.
METHODS: The DIN-LINK longitudinal patient database
sourced from medical records in UK was used to identify and
follow-up a cohort of patients with prescriptions for once weekly
administration of alendronate or risedronate. Follow-up period
was 12 month. The proportion of patients remaining on drug
treatment was calculated with the Kaplan-Meier product-limit
method. The log-rank test was used to evaluate the statistical sig-
niﬁcance of observed differences between treatment groups.
Results were considered to be statistically signiﬁcant if the cor-
responding p value was below 0.05. Analyses were performed
using SPSS for windows release 11.5.1. RESULTS: In the data-
base 2132 patients on weekly administration of alendronate and
356 patients on weekly administration of risedronate were iden-
tiﬁed. After 12 month 60.6% (95% CI 58%–63%) of patients
are remaining on alendronate and 69.7% (CI 65%–74%) of
patients are remaining on risedronate. The persistence with alen-
dronate is different to risedronate (p = 0.0015). The compliance
rate expressed as medication possession ratio (MPR) was 75.5%
and 83.3% for alendronate and risedronate, respectively. CON-
CLUSIONS: Results demonstrate a higher compliance and per-
sistence with weekly bisphosphonate than reported previously
from analyses in US claims databases. In fact, the study reveals
that patients taking once-a-week risedronate show a high com-
pliance rate (MPR > 80%). It has previously been demonstrated
that improving compliance in actual practice may signiﬁcantly
decrease osteoporosis related fracture risk. We conclude, that 
an once-a-week dosing regimen with risedronate provides
favourable compliance and persistence to effectively prevent
fractures.
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OBJECTIVES: To quantify the impact of a less frequent bis-
phosphonate regimen (weekly v daily) on compliance and 
persistence. METHODS: Data on bisphosphonate naïve post-
menopausal women in the US were derived from an administra-
tive claims database (1997–2003) covering 30 health plans. In
the UK and Germany data were derived from local Mediplus
databases (2001–2005) containing 2.5 million and 1.5 patients
respectively. Women were grouped into two cohorts; once daily
(OD—alendronate 5mg or 10mg and risedronate 5mg) and
once weekly (OW—alendronate 70mg and risedronate 35mg).
They were followed for at least 12 months from initial pre-
scription. Compliance was estimated as a Medication Possession
Ratio (MPR) and persistence as the number of days from initial
prescription to the date of discontinuation of therapy. RESULTS:
The number of women evaluated was 2,741 from US (OW =
731, OD = 2010), 5962 from UK (OW = 5102, OD = 860) and
288 from Germany (OW = 144, OD = 144). Mean age in each
country was 73 years. OW users had a signiﬁcantly higher MPR
than OD users (US: 56.3% v 37.7%, UK: 70.3% v 51.7%,
Germany: 51.7% v 37.7%, p < 0.0001). OW users also had a
signiﬁcantly higher persistence than OD users (US: 227 v 185
days, UK: 228 v 186 days, Germany: 227 v 172 days, p <
0.0001). More women stayed on weekly compared to a daily
regimen during the 12 month follow up (US: 44.2% v 31.7%,
UK: 43.6% v 33.3%, Germany: 46.5% v 27.8%, p < 0.0001).
CONCLUSIONS: Similar ﬁndings in different health care
systems conﬁrm that compliance and persistence with bisphos-
phonate treatment is improved substantially with a less frequent
dosing regimen. A further decrease may help patients use bis-
phosphonate treatment more regularly and longer term to max-
imise the therapeutic goal of reducing fracture rates.
